Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Total Debt (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Total Debt for 17 consecutive years, with $1.7 billion as the latest value for Q4 2025.

  • Quarterly Total Debt rose 54.17% to $1.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 billion through Dec 2025, up 54.17% year-over-year, with the annual reading at $1.7 billion for FY2025, 54.17% up from the prior year.
  • Total Debt hit $1.7 billion in Q4 2025 for Integra Lifesciences Holdings, up from $1.7 billion in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $1.7 billion in Q4 2025 to a low of $769.1 million in Q1 2023.
  • Historically, Total Debt has averaged $1.1 billion across 5 years, with a median of $870.5 million in 2022.
  • Biggest five-year swings in Total Debt: decreased 14.76% in 2021 and later surged 54.77% in 2024.
  • Year by year, Total Debt stood at $869.3 million in 2021, then dropped by 11.27% to $771.3 million in 2022, then increased by 7.04% to $825.6 million in 2023, then skyrocketed by 35.89% to $1.1 billion in 2024, then surged by 54.17% to $1.7 billion in 2025.
  • Business Quant data shows Total Debt for IART at $1.7 billion in Q4 2025, $1.7 billion in Q3 2025, and $1.7 billion in Q2 2025.